As the weather turns colder and the influenza season approaches, the importance of vaccination is once again in the spotlight. With the long Chuseok holiday expected to bring large-scale gatherings and travel, health authorities and vaccine companies are urging the public to receive flu shots to help curb the spread.

On September 29, SK bioscience announced the launch of its 2025-2026 influenza vaccination campaign. The initiative aims to raise awareness of flu prevention ahead of the Chuseok holiday and to encourage vaccination, particularly among high-risk groups with weaker immunity.

As part of the campaign, SK bioscience is distributing informational posters to clinics and hospitals nationwide, sharing flu-related content through its social media channels, and providing vaccine information on its website to support vaccination participation.

Earlier this year in June, the company signed a supply agreement with the Korea Disease Control and Prevention Agency (KDCA) to provide influenza vaccines sufficient for 2.4 million people under the National Immunization Program (NIP). These vaccines will be administered to children and adolescents aged six months to 13 years, seniors aged 65 and older, and pregnant women. Additional vaccines for non-NIP groups are also being distributed to hospitals and public institutions nationwide, with vaccinations continuing through early next year.

SK bioscience’s proprietary influenza vaccine, SKYCellflu®, is produced using cell culture technology, distinguishing it from the conventional egg-based method. This approach enables vaccination for people with egg allergies, eliminates the need for antibiotics or preservatives, and reduces the risk of adverse reactions. The lower likelihood of viral mutations during production also supports consistent vaccine effectiveness.

“Since the main flu vaccination season begins in October, it is important to get vaccinated ahead of Chuseok, when families gather together, to stay healthy,” said Soo-An Yoo, Head of Domestic Marketing at SK bioscience. “We will continue to ensure a stable vaccine supply so that the public can be vaccinated with confidence.”